Skip to main content

Table 1 Demographic data

From: Impact of relative dose intensity on bone marrow suppression induced by S-1: retrospective observational study

Characteristics (Number = 143) Values
Patient background
 Male (%) 92 (64.3)
 Age (years) 67.2 ± 10.6
 Height (cm) 160.7 ± 9.3
 Body weight (kg) 53.5 ± 11.3
 BMI (kg/m2) 20.7 ± 3.8
 BSA (m2) 1.54 ± 0.18
Clinical laboratory data
 WBC (×102/μL) 53.0 [44.0–70.0]
 ANC (×102/μL) 35.0 [23.0–54.0]
 ALC (×102/μL) 25.3 [14.8–33.0]
 Hb (g/dL) 11.9 ± 1.5
 Plt (×104/μL) 21.4 [17.7–26.5]
 AST (IU/L) 22.0 [18.0–31.0]
 ALT (IU/L) 16.0 [11.0–24.0]
 Total bilirubin (mg/dL) 0.6 [0.5–0.9]
 Serum albumin (g/dL) 3.8 [3.5–4.1]
 Serum creatinine (mg/dL) 0.7 [0.6–0.8]
 eGFRa (mL/min/1.73 m2) 78.1 ± 21.5
Indication for S-1 treatment
 Gastrointestinal cancer (%) 110 (76.9)
 Lung cancer (%) 9 (6.3)
 Breast cancer (%) 9 (6.3)
 Other cancers (%) 15 (10.5)
 Clinical cancer stage ≥III (%) 96 (67.1)
Details of S-1 treatment
 RDIb (%) 78.8 [70.7–85.8]
 RDIb > 70% (%) 113 (79.0)
 RDIb > 75% (%) 85 (59.4)
 RDIb > 80% (%) 68 (47.6)
 Presence of combination chemotherapy (%) 51 (35.7)
 Prior history of cytotoxic chemotherapy (%) 52 (36.4)
  1. Continuous data are expressed as mean ± SD or median [IQR] as appropriate. Categorical data are expressed as number (%)
  2. SD standard deviation, IQR interquartile range, BMI body mass index, BSA body surface area, WBC white blood cell count, ANC absolute neutrophil count, ALC absolute lymphocyte count, Hb hemoglobin, Plt platelet count, AST aspartate transaminase, ALT alanine aminotransferase, eGFR estimated glomerular filtration rate, RDI relative dose intensity
  3. aeGFR was calculated using a prediction equation
  4. bRDI is the ratio of the actual dose intensity to the planned dose intensity